These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 686899)
1. Correlation of estrophilin content of primary mammary cancer to eventual endocrine treatment. Block GE; Ellis RS; DeSombre E; Jensen E Ann Surg; 1978 Sep; 188(3):372-6. PubMed ID: 686899 [TBL] [Abstract][Full Text] [Related]
2. The prediction of hormonal dependency of mammary cancer. Block GE; Jensen EV; Polley TZ Ann Surg; 1975 Sep; 182(3):342-52. PubMed ID: 169754 [TBL] [Abstract][Full Text] [Related]
3. Steroid receptors and response to endocrine ablations in women with metastatic cancer of the breast. Dao TL; Nemoto T Cancer; 1980 Dec; 46(12 Suppl):2779-82. PubMed ID: 7448720 [TBL] [Abstract][Full Text] [Related]
4. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339 [TBL] [Abstract][Full Text] [Related]
5. Estrophilin assays in breast cancer: quantitative features and application to the mastectomy specimen. DeSombre ER; Jensen EV Cancer; 1980 Dec; 46(12 Suppl):2783-8. PubMed ID: 7448721 [TBL] [Abstract][Full Text] [Related]
6. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction. Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476 [TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor and endocrine responsiveness in Japanese versus American breast cancer patients. Nomura Y; Kobayashi S; Takatani O; Sugano H; Matsumoto K; McGuire WL Cancer Res; 1977 Jan; 37(1):106-10. PubMed ID: 830399 [TBL] [Abstract][Full Text] [Related]
8. Steroid receptors in breast cancer. Desombre ER Monogr Pathol; 1984; (25):149-74. PubMed ID: 6377047 [TBL] [Abstract][Full Text] [Related]
9. Clinical application of estrogen receptor in breast cancer. Singhakowinta A; Saunders DE; Brooks SC; Samal B; Vaitkevicius VK Cancer; 1980 Dec; 46(12 Suppl):2932-8. PubMed ID: 7448740 [TBL] [Abstract][Full Text] [Related]
10. Management of breast cancer. Cohen IA; Keller JH; Abate MA Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963 [TBL] [Abstract][Full Text] [Related]
11. Estrogen receptors and breast cancer: prognostic and therapeutic implications. Gapinski PV; Donegan WL Surgery; 1980 Sep; 88(3):386-93. PubMed ID: 7414516 [TBL] [Abstract][Full Text] [Related]
12. Randomized sequential hormonal therapy vs adrenalectomy for metastatic breast carcinoma. Yonemoto RH; Tan MS; Byron RL; Riihimaki DU; Keating J; Jacobs W Cancer; 1977 Feb; 39(2):547-55. PubMed ID: 319892 [TBL] [Abstract][Full Text] [Related]
13. Hormone dependency of breast cancer. Jensen EV Cancer; 1981 May; 47(10):2319-26. PubMed ID: 7272888 [TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer. Hartman AR; Fleming GF; Dillon JJ Clin Breast Cancer; 2001 Jul; 2(2):138-43; discussion 144. PubMed ID: 11899785 [TBL] [Abstract][Full Text] [Related]
15. Selection of chemotherapy for metastatic mammary cancer by effect on cesium-131 uptake. Ferguson DJ; Harper PV Cancer; 1977 Sep; 40(3):977-86. PubMed ID: 902246 [TBL] [Abstract][Full Text] [Related]
16. Relationship between primary breast tumor receptor status and patient survival. Blamey RW; Bishop HM; Blake JR; Doyle PJ; Elston CW; Haybittle JL; Nicholson RI; Griffiths K Cancer; 1980 Dec; 46(12 Suppl):2765-9. PubMed ID: 7448717 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153 [TBL] [Abstract][Full Text] [Related]
18. High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS? Regierer AC; Wolters R; Kurzeder C; Wöckel A; Novopashenny I; Possinger K; Wischnewsky MB; Kreienberg R Breast Cancer Res Treat; 2011 Jul; 128(1):273-81. PubMed ID: 21210206 [TBL] [Abstract][Full Text] [Related]
19. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B; J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406 [TBL] [Abstract][Full Text] [Related]
20. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]